Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Department of The Operating Room, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Aesthetic Plast Surg. 2021 Dec;45(6):2581-2590. doi: 10.1007/s00266-021-02509-8. Epub 2021 Aug 4.
Biological matrix-assisted one-stage implant-based breast reconstruction (IBBR) could improve the inframammary fold to achieve good esthetic results. However, whether biological matrix-assisted one-stage IBBR yields better postoperative outcomes compared with two-stage IBBR remains unclear. We aimed to compare and analyze surgical complications and patient-reported outcomes (PROs) based on the BREAST-Q version 2.0 questionnaire between biological matrix-assisted one-stage IBBR and traditional two-stage IBBR.
From May 2015 to June 2019, eligible patients who underwent SIS matrix-assisted one-stage IBBR or two-stage IBBR were enrolled in this retrospective cohort study. PROs were measured with BREAST-Q version 2.0, which scored the health-related quality of life, satisfaction, and experience domains. Complications were divided into major complications (patients requiring reoperation) and minor complications (patients who could be treated in the dressing room). PROs and complications were compared between the SIS matrix-assisted one-stage IBBR and two-stage IBBR groups. A multivariate linear regression analysis was used to identify the social and surgical factors that affected PROs.
At our institution, 124 eligible patients were recruited. Seventy-nine patients (63.7%) underwent SIS matrix-assisted one-stage IBBR reconstruction, and 45 patients (36.3%) underwent tissue expander/implant reconstruction (two-stage IBBR). Postoperative BREAST-Q version 2.0 was completed by 68 of 79 patients (86.1%) in the SIS matrix-assisted one-stage IBBR group and by 35 of 45 patients (77.8%) in the two-stage IBBR group. In the satisfaction-related quality of life domain, satisfaction with breast was 9.27 points higher in the SIS matrix-assisted one-stage IBBR group (p = 0.012) compared with the two-stage IBBR group. The multivariate linear regression analysis showed that implant volume (p = 0.031) and postoperative radiotherapy (p = 0.036) significantly influenced the PRO of satisfaction with breast. However, patients in the SIS matrix-assisted one-stage IBBR group had a higher minor complication rate compared with patients in the two-stage IBBR group (p = 0.026).
Our retrospective study showed that although patients treated with biological matrix-assisted one-stage IBBR tended to have higher postoperative complication rates, this technique correlated with better PROs compared with two-stage IBBR.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
生物基质辅助的一期基于植入物的乳房重建(IBBR)可以改善乳房下皱襞,以获得良好的美容效果。然而,生物基质辅助的一期 IBBR 是否比两期 IBBR 产生更好的术后结果尚不清楚。我们旨在比较和分析基于 BREAST-Q 第 2.0 版问卷的生物基质辅助一期 IBBR 和传统两期 IBBR 的手术并发症和患者报告的结局(PRO)。
从 2015 年 5 月至 2019 年 6 月,我们招募了接受 SIS 基质辅助一期 IBBR 或两期 IBBR 的合格患者进行这项回顾性队列研究。使用 BREAST-Q 第 2.0 版测量 PRO,该版本对健康相关生活质量、满意度和体验领域进行评分。并发症分为主要并发症(需要再次手术的患者)和次要并发症(可在换药室治疗的患者)。比较 SIS 基质辅助一期 IBBR 和两期 IBBR 组之间的 PRO 和并发症。采用多元线性回归分析确定影响 PRO 的社会和手术因素。
在我们的机构中,招募了 124 名合格的患者。79 名患者(63.7%)接受了 SIS 基质辅助一期 IBBR 重建,45 名患者(36.3%)接受了组织扩张器/植入物重建(两期 IBBR)。在 SIS 基质辅助一期 IBBR 组中,有 68 名患者(86.1%)完成了术后 BREAST-Q 第 2.0 版,在两期 IBBR 组中有 35 名患者(77.8%)完成了术后 BREAST-Q 第 2.0 版。在与满意度相关的生活质量领域,SIS 基质辅助一期 IBBR 组的乳房满意度比两期 IBBR 组高 9.27 分(p=0.012)。多元线性回归分析显示,植入物体积(p=0.031)和术后放疗(p=0.036)显著影响乳房满意度的 PRO。然而,与两期 IBBR 组相比,SIS 基质辅助一期 IBBR 组的次要并发症发生率更高(p=0.026)。
我们的回顾性研究表明,尽管接受生物基质辅助一期 IBBR 治疗的患者术后并发症发生率较高,但与两期 IBBR 相比,该技术与更好的 PRO 相关。
证据水平 III:本杂志要求作者为每篇文章指定一个证据水平。有关这些循证医学评级的完整描述,请参考目录或在线说明 www.springer.com/00266。